{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:43:03Z","timestamp":1793209383926,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1136\/ijgc-2024-005412","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T13:21:11Z","timestamp":1713273671000},"page":"1283-1289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["ENGOT-EN20\/GOG-3083\/XPORT-EC-042 \u2013 A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct05611931","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05611931","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05611931","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"Ignace","family":"Vergote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-4345","authenticated-orcid":false,"given":"Alejandro","family":"Perez Fidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-6305","authenticated-orcid":false,"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-2061","authenticated-orcid":false,"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-6623","authenticated-orcid":false,"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-4582","authenticated-orcid":false,"given":"Jacob","family":"Korach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Barlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos A.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-721X","authenticated-orcid":false,"given":"Toon","family":"van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-8610","authenticated-orcid":false,"given":"Debra","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoland","family":"Antill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-1010","authenticated-orcid":false,"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratheek","family":"Kalyanapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-3096","authenticated-orcid":false,"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005412_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","article-title":"Endometrial cancer","volume":"7","author":"Makker","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1136\/ijgc-2024-005412_bb0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005412_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061478","article-title":"The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions","volume":"13","author":"Alexa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2024-005412_bb0025","volume":"34","author":"Mirza","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005412_bb0030","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005412_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2021.01.025","article-title":"Mutated P53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced\/recurrent endometrial cancer: an NRG Oncology study","volume":"161","author":"Leslie","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005412_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2024-005412_bb0045","first-page":"1317","article-title":"Chemoresistance and targeting of growth factors\/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer","volume":"8","author":"Guo","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1136\/ijgc-2024-005412_bb0050","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.currproblcancer.2023.100963","article-title":"Selinexor in patients with advanced and recurrent endometrial cancer","volume":"47","author":"Bogani","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"10.1136\/ijgc-2024-005412_bb0055","author":"Karyopharm Therapeutics Inc","year":"2022","journal-title":"XPOVIO\u00ae (Selinexor), package insert"},{"key":"10.1136\/ijgc-2024-005412_bb0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","article-title":"Phase 2 study of the Exportin 1 inhibitor Selinexor in patients with recurrent gynecological malignancies","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005412_bb0065","first-page":"A12","author":"Sehouli","year":"2024","journal-title":"187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5\/GOG-3055\/SIENDO study"},{"key":"10.1136\/ijgc-2024-005412_bb0070","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005412_bb0075","unstructured":"ClinicalTrials.gov. Selinexor in maintenance therapy after systemic therapy for participants with P53 wild-type, advanced or recurrent endometrial carcinoma. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05611931 [Accessed 3 Aug 2023]."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:26:30Z","timestamp":1764062790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24000148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1048891X24000148"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005412","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENGOT-EN20\/GOG-3083\/XPORT-EC-042 \u2013 A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}